2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…2021 American Transplant Congress
Use of Donor Blood Expedites HCV Genotyping and Allows Earlier DAA Initiation for Recipients of HCV+ Kidneys
Tranplant Institute, NYU Langone Health, New York, NY
*Purpose: Utilization of HCV viremic donor kidneys for transplant into HCV naïve recipients has become more widespread, yet best practices governing the initiation, timing or…2020 American Transplant Congress
Unrealized Potential Utilization of HCV+ Deceased-Donor Kidneys and Livers
*Purpose: In the era of new, direct-acting antiviral therapy for hepatitis C virus (HCV), HCV+ deceased-donor organs can be transplanted into HCV- recipients with excellent…2020 American Transplant Congress
Transplantation of HCV Positive Kidneys Confers Excellent Outcomes for HCV Infected and Uninfected Recipients
Montefiore Medical Center, Bronx, NY
*Purpose: Hepatitis C positive (HCV+) donor kidneys were previously transplanted only into HCV infected recipients (D+/R+). Availability of direct acting anti-virals (DAA) has facilitated the…2020 American Transplant Congress
The Trend of Non-Utilization and Decline of Hepatitis C Virus Antibody-Positive Deceased Donor Kidneys
*Purpose: With more transplant centers are accepting hepatitis C virus infected (HCV+) deceased donor kidneys (dHCV+), the trend of non-utilization and decline of these organs…2020 American Transplant Congress
Hepatitis C and Racial Disparity in Liver Transplant Waitlist Additions: Separate Not Equal
*Purpose: In 2014, direct-acting antivirals (DAAs) became available as a treatment option for Hepatitis C Virus (HCV) with successful results. Since the implementation of DAAs,…2020 American Transplant Congress
Survey of Clinician Opinions on Use of Organ Transplants from Hepatitis C Virus Positive Donors: Identifying & Overcoming Barriers
*Purpose: Increasing the use of Hepatitis C Virus (HCV) viremic (Nucleic Acid Testing (NAT)+) donor organs for HCV uninfected (HCV-) patients is a potential approach…2020 American Transplant Congress
Hepatitis C-Infected Donors and Hepatitis C-Infected Recipients: Analysis of Renal Transplant Outcomes
*Purpose: Increased utilization of hepatitis C virus infected organs could reduce the supply demand mismatch in organ transplantation. At this time, there is little data…2020 American Transplant Congress
Re-Transplantation Outcomes in the United States Before and after DAA-Introduction
Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: The success of direct-acting antiviral (DAA) therapy has led to the widespread treatment of HCV and near-universal cure for chronically infected patients and improved…2020 American Transplant Congress
Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kideney Transplant Recipients
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous trials in kidney transplantation (KT) have described a 12-week course of direct-acting anti-viral drugs (DAA) to treat HCV transmission from infected donors to…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 28
- Next Page »